References
- Mullard A . 2014 FDA drug approvals. Nat. Rev. Drug Discov.14 (2), 77–81 (2015).
- Scannell JW , BlanckleyA, BoldonH, WarringtonB. Diagnosing the decline in pharmaceutical R&D. Nat. Rev. Drug Discov.11 (3), 191–200 (2012).
- Paul SM , MytelkaDS, DunwiddieCTet al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov.9 (3), 203–214 (2010).
- Macarron R , BanksMN, BojanicDet al. Impact of high-throughput screening in biomedical research. Nat. Rev. Drug Discov.10 (3), 188–195 (2011).
- Dahlin JL , WaltersMA. The essential roles of chemistry in high-throughput screening triage. Future Med. Chem.6 (11), 1265–1290 (2014).
- Kuhnert M , KosterH, BartholomausRet al. Tracing binding modes in hit-to-lead optimization: chameleon-like poses of aspartic protease inhibitors. Angew. Chem. Int. Ed. Engl.54 (9), 2849–2853 (2015).
- Soares KM , BlackmonN, ShunTYet al. Profiling the NIH small molecule repository for compounds that generate H2O2 by redox cycling in reducing environments. Assay Drug Dev. Technol.8 (2), 152–174 (2010).
- Hermann JC , ChenY, WartchowCet al. Metal impurities cause false positives in high throughput screening campaigns. ACS Med. Chem. Lett.4 (2), 197–200 (2013).
- Baell J , WaltersMA. Chemical con artists foil drug discovery. Nature513 (7519), 481–483 (2014).
- Seidler J , McGovernSL, DomanTN, ShoichetBK. Identification and prediction of promiscuous aggregating inhibitors among known drugs. J. Med. Chem.46 (21), 4477–4486 (2003).
- Devine SM , MulcairMD, DebonoCOet al. Promiscuous 2-aminothiazoles (PrATs): a frequent hitting scaffold. J. Med. Chem.58 (3), 1205–1214 (2015).
- Brem J , van BerkelSS, AikWet al. Rhodanine hydrolysis leads to potent thioenolate mediated metallo-β-lactamase inhibition. Nat. Chem.6, 1084–1090 (2014).
- Shoichet BK . Interpreting steep dose-response curves in early inhibitor discovery. J. Med. Chem.49 (25), 7274–7277 (2006).
- Hann MM , KeseruG. Finding the sweet spot: the role of nature and nurture in medicinal chemistry. Nat. Rev. Drug Discov.11 (5), 355–365 (2012).
- Academic Drug Discovery Consortium . www.addconsortium.org
- Frye S , CrosbyM, EdwardsT, JulianoR. US academic drug discovery. Nat. Rev. Drug Discov.10 (6), 409–410 (2011).
- Tralau-Stewart C , LowCMR, MarlinN. UK academic drug discovery. Nat. Rev. Drug Discov.13 (1), 15–16 (2014).
- Shanks E , KettelerR, EbnerD. Academic drug discovery within the United Kingdom: a reassessment. Nat. Rev. Drug Discov.14 (7), 510–513 (2015).
- Kogej T , BlombergN, GreasleyPet al. Big pharma screening collections: more of the same or unique libraries? The AstraZeneca–Bayer Pharma AG case. Drug Discov. Today18 (19–20), 1014–1024 (2013).
- Besnard J , JonesPS, HopkinsAL, PanniferAD. The Joint European Compound Library: boosting precompetitive research. Drug Discov. Today20 (2), 181–186 (2015).